Public Hearing | Mixed
Event Title
Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing
September 14, 2026
- Date:
- September 14, 2026
- Time:
- 12:30 p.m. - 4:30 p.m. ET
On This Page
The U.S. Food and Drug Administration (FDA) is announcing a public hearing, held in collaboration with federal partners, to obtain feedback and perspectives on issues associated with the potential future therapeutic use of drug products containing a psychedelic drug substance in supervised and supportive settings.
More information is available in the Federal Register :: Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments.
Meeting Location
Attend in Person or Online
Virtual: Via webcast
In Person: FDA’s White Oak Campus, Building 31, Room 1503 - Great Room
10903 New Hampshire Avenue, Silver Spring, Maryland 20993
FDA Campus Information (e.g., local airports, directions, and local hotels)
Registration and Requests to Present Oral Comment
Register to attend the Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing. All requests to present at the hearing must be received on or before 11:59 ET on August 21, 2026.
Submit Written Comments
Written comments must be submitted to the Federal Register :: Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments electronic filing system on or before 11:59 p.m. ET on October 5, 2026.
More Information
Questions
Email questions to PsychedelicsHearing@fda.hhs.gov.